Kenvue, Inc. (KVUE) Q2 2025 Earnings Report
MX:KVUE Q2 2025 EPS Results
- Actual EPS
- MXN 5.45
- Consensus EPS
- MXN 5.32
- Beat/Miss
- Beat by +MXN 0.13
- One Year Ago EPS
- MXN 6.01
MX:KVUE Q2 2025 Revenue Results
- Actual Revenue
- MXN 72.14B
- Expected Revenue
- MXN 72.40B
- Beat/Miss
- Missed by -MXN 258.99M
- YoY Revenue Growth
- -4.02%
Earnings Announcement Details
- Quarter
- Q2 2025
- Date
- 07/14/2025
- Time
- Before Open
- Conference Call
- Monday, July 14, 2025
Kenvue, Inc.'s next earnings date is estimated for February 11, 2027, based on past reporting schedules.
Q2 2025 Earnings Call Audio
No earnings call audio is available for this earnings event.
Q2 2025 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2025 Earnings Call Summary
The earnings call highlighted Kenvue's strengths in market share gains and leadership improvements but was overshadowed by underwhelming financial performance and challenges in key markets. The revised guidance and focus on strategic alternatives suggest a period of transition and uncertainty.
During Kenvue's Second Quarter 2025 Earnings Conference Call, the company revised its guidance for fiscal 2025, projecting organic sales to decline in the low single digits with a roughly neutral impact from currency fluctuations. The adjusted operating margin is expected to contract due to strategic price investments, fixed cost deleverage, and inflationary pressures, which productivity initiatives may not fully offset. Consequently, adjusted diluted EPS is anticipated to range between $1 to $1.05, considering a low single-digit drag from currency. The company highlighted a challenging second quarter, with organic sales declining by 4.2% and adjusted operating margin decreasing by 10 basis points to 22.7%, leading to an adjusted diluted EPS of $0.29. Despite these results, Kenvue remains committed to enhancing operational rigor, improving execution, and strategically reviewing alternatives to unlock shareholder value.
- Strong Market Share in Self CareIn the U.S., 83% of Kenvue's Self Care business held or gained market share, with ZYRTEC growing household penetration and Tylenol achieving its 12th consecutive quarter of share improvement.
- Sequential Improvement in Skin Health and BeautyNeutrogena Face returned to year-over-year consumption growth in the U.S. during Q2, and global consumption of Skin Health and Beauty brands stabilized for the first time in over a year.
- Leadership and Capabilities StrengtheningKenvue appointed new leaders, including Andy Dasgupta and Mike Wondrasch, and enhanced capabilities in marketing, sales, digital, and AI.
- Success in EMEA and Latin AmericaThe company saw positive performance in EMEA and Latin America, contributing to a more stable global consumption trend.
MX:KVUE Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 11, 2027 | 2026 (Q4) | 4.89- | 5.07 | ― | ― |
| Oct 30, 2026 | 2026 (Q3) | 5.495.45 | 5.26 | 3.57% (+0.19) | |
| Aug 06, 2026 | 2026 (Q2) | 5.995.83 | 5.45 | 6.90% (+0.38) | |
| May 07, 2026 | 2026 (Q1) | 4.926.01 | 4.51 | 33.33% (+1.50) | |
| Feb 17, 2026 | 2025 (Q4) | 4.135.07 | 4.89 | 3.85% (+0.19) | |
| Sep 28, 2025 | 2025 (Q3) | 4.905.26 | 5.26 | 0.00% (+0.00) | |
| Jul 14, 2025 | 2025 (Q2) | 5.325.45 | 6.01 | -9.38% (-0.56) | |
| May 08, 2025 | 2025 (Q1) | 4.274.51 | 5.26 | -14.29% (-0.75) | |
| Feb 06, 2025 | 2024 (Q4) | 4.834.89 | 5.83 | -16.13% (-0.94) | |
| Nov 07, 2024 | 2024 (Q3) | 5.115.26 | 5.83 | -9.68% (-0.56) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
